SG10201909596RA - Synthesis of Tyrosine Kinase Inhibitors - Google Patents

Synthesis of Tyrosine Kinase Inhibitors

Info

Publication number
SG10201909596RA
SG10201909596RA SG10201909596RA SG10201909596RA SG10201909596RA SG 10201909596R A SG10201909596R A SG 10201909596RA SG 10201909596R A SG10201909596R A SG 10201909596RA SG 10201909596R A SG10201909596R A SG 10201909596RA SG 10201909596R A SG10201909596R A SG 10201909596RA
Authority
SG
Singapore
Prior art keywords
synthesis
tyrosine kinase
kinase inhibitors
inhibitors
tyrosine
Prior art date
Application number
SG10201909596RA
Inventor
Abraham Rajkumar Gurubatham
Lin Xiangliang
Original Assignee
Esco Aster Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esco Aster Pte Ltd filed Critical Esco Aster Pte Ltd
Priority to SG10201909596RA priority Critical patent/SG10201909596RA/en
Priority to CN202080073377.3A priority patent/CN114585615A/en
Priority to JP2022547807A priority patent/JP2023503193A/en
Priority to PCT/EP2020/078761 priority patent/WO2021074138A1/en
Priority to AU2020366118A priority patent/AU2020366118A1/en
Priority to KR1020227014080A priority patent/KR20220124679A/en
Priority to EP20792606.4A priority patent/EP4045494B1/en
Priority to TW109135376A priority patent/TWI832015B/en
Priority to BR112022007107A priority patent/BR112022007107A2/en
Priority to US17/769,177 priority patent/US20230065387A1/en
Publication of SG10201909596RA publication Critical patent/SG10201909596RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
SG10201909596RA 2019-10-14 2019-10-14 Synthesis of Tyrosine Kinase Inhibitors SG10201909596RA (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG10201909596RA SG10201909596RA (en) 2019-10-14 2019-10-14 Synthesis of Tyrosine Kinase Inhibitors
CN202080073377.3A CN114585615A (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine
JP2022547807A JP2023503193A (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-N1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
PCT/EP2020/078761 WO2021074138A1 (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
AU2020366118A AU2020366118A1 (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
KR1020227014080A KR20220124679A (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-N1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
EP20792606.4A EP4045494B1 (en) 2019-10-14 2020-10-13 Synthesis of 6-methyl-n1-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine
TW109135376A TWI832015B (en) 2019-10-14 2020-10-13 Synthesis of tyrosine kinase inhibitors
BR112022007107A BR112022007107A2 (en) 2019-10-14 2020-10-13 METHOD FOR SYNTHESIS OF A COMPOUND
US17/769,177 US20230065387A1 (en) 2019-10-14 2020-10-13 Synthesis of tyrosine kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201909596RA SG10201909596RA (en) 2019-10-14 2019-10-14 Synthesis of Tyrosine Kinase Inhibitors

Publications (1)

Publication Number Publication Date
SG10201909596RA true SG10201909596RA (en) 2021-05-28

Family

ID=72895951

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201909596RA SG10201909596RA (en) 2019-10-14 2019-10-14 Synthesis of Tyrosine Kinase Inhibitors

Country Status (9)

Country Link
US (1) US20230065387A1 (en)
EP (1) EP4045494B1 (en)
JP (1) JP2023503193A (en)
KR (1) KR20220124679A (en)
CN (1) CN114585615A (en)
AU (1) AU2020366118A1 (en)
BR (1) BR112022007107A2 (en)
SG (1) SG10201909596RA (en)
WO (1) WO2021074138A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113419004B (en) * 2021-06-22 2023-04-18 海南鑫开源医药科技有限公司 Method for detecting impurities in methyl 3-amino-4-methylbenzoate
CN114853734A (en) * 2022-06-14 2022-08-05 海南鑫开源医药科技有限公司 Preparation method of nilotinib free base

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
CN100537563C (en) * 2006-07-12 2009-09-09 浙江省医学科学院 Process for preparing N-phenyl-2-pyrimidyl amine derivative
KR101286780B1 (en) * 2011-02-01 2013-07-17 에스티팜 주식회사 A bicarbonate salt and a method of preparing imatinib and salt using the same
WO2013035102A1 (en) * 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
WO2015087343A2 (en) * 2013-12-09 2015-06-18 Laurus Labs Private Limited An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof
CN105801559B (en) * 2016-04-28 2019-03-01 北京化工大学 The preparation method of 4- methyl -3- [[4- (3- pyridyl group) -2- pyrimidine radicals] amino] ethyl benzoate
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt

Also Published As

Publication number Publication date
WO2021074138A1 (en) 2021-04-22
EP4045494C0 (en) 2023-10-11
EP4045494B1 (en) 2023-10-11
US20230065387A1 (en) 2023-03-02
KR20220124679A (en) 2022-09-14
AU2020366118A1 (en) 2022-05-12
TW202128641A (en) 2021-08-01
CN114585615A (en) 2022-06-03
EP4045494A1 (en) 2022-08-24
BR112022007107A2 (en) 2022-07-05
JP2023503193A (en) 2023-01-26

Similar Documents

Publication Publication Date Title
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
IL274716A (en) Synthesis of a bruton's tyrosine kinase inhibitor
IL271930A (en) Heterocyclic inhibitors of atr kinase
EP4069212A4 (en) Inhibitors of hif-2alpha
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL282801A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
IL281805A (en) Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
EP3962908A4 (en) Heterocyclic inhibitors of tyrosine kinase
EP3668839A4 (en) Heterocyclic inhibitors of atr kinase
IL283599A (en) Tyrosine kinase inhibitors, compositions and methods there of
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EP3765008A4 (en) Heterocyclic inhibitors of atr kinase
KR20220035925A (en) Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
EP3328496A4 (en) Inhibitors of ack1/tnk2 tyrosine kinase
SG11202109781QA (en) Uses of phosphodiesterase inhibitors
IL288387A (en) Small molecule inhibitors of nf-kb inducing kinase
EP4108666A4 (en) Multi-target tyrosine kinase inhibitor
EP3986411A4 (en) Small molecule inhibitors of src tyrosine kinase
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
IL281599A (en) Tyk2 kinase inhibitors
EP3999064A4 (en) Inhibitors of tyrosine kinase
EP4074697A4 (en) Novel adamantane derivatives as inhibitors of focal adhesion kinase
GB201807845D0 (en) Kinase Inhibitors
ZA202103858B (en) Tyrosine kinase inhibitors, compositions and methods there of